Avid Bioservices Inc

Avid Bioservices — Peregrine Pharmaceuticals — Proxy Contest (October 2017)

30 slides from Avid Bioservices's proxy contest presentation, Oct 30, 2017

  1. Slide 1: Peregrine Pharmaceuticals: Shareholders Seeking Change

    PEREGRINE PHARMACEUTICALS, INC. RONIN TRADING LLC & SW INVESTMENT MANAGEMENT LLC SHAREHOLDERS SEEKING CHANGE October 30, 2017

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation is for discussion and general informational purposes only. It does not have regard to the specific investment objective, financial situation, suitability, or the particular need of any specific person who may receive this presentation, and should not be taken as advice o

  3. Slide 3: Who We Are

    WHO WE ARE  Ronin Trading, LLC (“Ronin”) is a Chicago-based proprietary trading firm managed by John Stafford III  SW Investment Management LLC (“SWIM”) is a Chicago-based fund manager founded and managed by Stephen White  Combined, Ronin and SWIM (“We”) own approximately 9.6% of Peregrine Pharma

  4. Slide 4: Brief History of Our Interaction

    BRIEF HISTORY OF OUR INTERACTION  In early 2017, we had held multiple discussions with Peregrine’s management to express our strong disapproval of the Company’s poor corporate governance, interest misalignment with shareholders, equity dilution, financial losses, and inexperienced Board (among othe

  5. Slide 5: Typical Activism vs Our Approach

    TYPICAL ACTIVISM VS OUR APPROACH Common Activist Strategy Our Strategy We are NOT nominating ourselves to Peregrine’s Board. We believe the Company’s Board should be composed of high Elect themselves to a company’s board quality, industry professionals who have records of shareholder value creation

  6. Slide 6: Peregrine's Incumbent Board

    PEREGRINE’S INCUMBENT BOARD These four people represented the entirety of Peregrine’s Board from December 16, 2008 – September 11, 2017 -66% stock performance Director Role Tenure over this period Carlton Johnson Non-employee Director; Chairman 18 Years “Incumbent Independent (Non- Eric Swartz Non-e

  7. Slide 7: Peregrine's Slate Is Unacceptable – More of the Same

    PEREGRINE’S SLATE IS UNACCEPTABLE – MORE OF THE SAME PPHM Stock  Incumbent Board Members have carefully composed Incumbents Price the Board to retain control among themselves Majority Director During Director Since Tenure Profession Incumbent? Independent  Incumbent Independent Board Members have

  8. Slide 8: Peregrine Cannot Afford More R&D

    PEREGRINE CANNOT AFFORD MORE R&D Peregrine – R&D vs Net Income (millions) $80  Peregrine cannot afford more R&D without simultaneously $60 $60 destroying the value of Avid Bioservices, which we believe is an $43 $36 excellent growth business $40 $25 $30 $28 $30 $24  In FY2016 and FY2017, R&D expen

  9. Slide 9: Excessive Shareholder Dilution

    EXCESSIVE SHAREHOLDER DILUTION Peregrine Fully Diluted Shares Outstanding (millions) 50 45 40 35  To fund R&D, Peregrine has diluted its shareholders by an average of 30 30% annually since 2010 and 640% cumulatively 640% dilution since 2010 25  All else equal, a shareholder of Peregrine would have

  10. Slide 10: Avid Bioservices – Overview

    AVID BIOSERVICES – OVERVIEW Key points about Avid Bioservices Key points about the CDMO business  Avid Bioservices is a Contract Design and Manufacturing  CDMOs are paid based on API volumes and typically do not have Organization (“CDMO”) that produces Advanced Pharmaceutical any direct price risk

  11. Slide 11: Avid Bioservices – An Excellent Growth Business

    AVID BIOSERVICES – AN EXCELLENT GROWTH BUSINESS Avid Bioservices (millions) $70  Avid Bioservices has grown quickly in spite of Peregrine’s $58 $60 management and Board allocating hundred of millions in capital away from it $50 $44  We believe that Avid Bioservices’ results would be significantly

  12. Slide 12: Avid Bioservices – Positioned for Success

    AVID BIOSERVICES – POSITIONED FOR SUCCESS  “Our data shows that demand will be outstripping capacity probably for about the next five years. The other thing that I'd like to point out is we know that 40% of the pipeline is currently biologics and 70% of the pipeline in biologics are going to requir

  13. Slide 13: Avid Bioservices Should Be a Standalone Company

    AVID BIOSERVICES SHOULD BE A STANDALONE COMPANY  Avid Bioservices and Peregrine’s clinical development programs are two incredibly different businesses – different capital requirements, scientific and operational expertise, revenue streams, etc Avid Bioservices  Avid Bioservices is a great busines

  14. Slide 14: Does This Sound Like Good Management?

    DOES THIS SOUND LIKE GOOD MANAGEMENT? “Peregrine Pharmaceuticals announces reverse stock split…Intended to Enable Continued Listing on the NASDAQ Capital Market.” – July 7, 2017, Company press release “…we have concluded that there is substantial doubt about our ability to continue as a going concer

  15. Slide 15: Steven King, CEO, Unfit to Remain at Peregrine

    STEVEN KING, CEO, UNFIT TO REMAIN AT PEREGRINE  Under Mr. King’s leadership as CEO since March 19, 2003, Peregrine has:  Increased fully diluted shares outstanding by 1,252% cumulatively; 20.4% annualized  Never reported a single quarterly net profit  Not developed any drugs to commercial succes

  16. Slide 16: Beware of Steven King's Excitement

    BEWARE OF STEVEN KING’S “EXCITEMENT” Peregrine Stock Price vs. Steven King's Excitement aka “What They Say vs What They Do”  Despite Peregrine’s continual struggles under Mr. $70.00 14 King’s leadership, one thing has remained amazingly consistent: Mr. King is constantly $60.00 12 “excited” $50.00

  17. Slide 17: Named Executive Officers – Lack of Relevant Experience

    NAMED EXECUTIVE OFFICERS – LACK OF RELEVANT EXPERIENCE Year Started Person Title at Peregrine Prior CDMO Experience? Steven King CEO 1997 ❌ None We would like the Board, and specifically its Paul Lytle CFO 1997 ❌ None three newest members, Messrs. Lias, Bamforth and Walsh, to publicly justify Mr. Ly

  18. Slide 18: A Plan to Create Value

    A PLAN TO CREATE VALUE 1. Suspend clinical development business Key Points a) Monetize all clinical development assets ▪ This is a SIMPLE plan that can be implemented quickly, at minimal cost to shareholders b) Immediately realign cost structure ▪ A monetization process by capable and aligned direct

  19. Slide 19: Peregrine's Board Tried to Sell Avid Bioservices

    PEREGRINE’S BOARD TRIED TO SELL AVID BIOSERVICES  In late-2016, Peregrine hired RBC Capital Markets to run a sale process for Avid Bioservices  Management appears to have wanted to use the sale proceeds to fund more R&D, as well as capitalize the company to continue extremely high compensation for

  20. Slide 20: The Board Dawdles, Shareholders Lose

    THE BOARD DAWDLES, SHAREHOLDERS LOSE Peregrine Fully Diluted Shares Outstanding (millions) 46 44.8  While Peregrine’s Board fumbled with what to do with the 44 43.0 Company’s strategy, they diluted shareholders by 28% in just four quarters 42 28% dilution  We believe the recent dilution suffered b

  21. Slide 21: Peregrine's Slate Is Not Change

    PEREGRINE’S SLATE IS NOT CHANGE  Peregrine’s slate retains control of the Board with Incumbent Board Members  Incumbent Board Members have overseen Peregrine’s enormous shareholder value destruction for many years  Incumbent Independent Board Members have absolutely no experience with CDMOs or an

  22. Slide 22: Corp Gov Failing #1 – Immaterial Ownership

    CORP GOV FAILING #1 – IMMATERIAL OWNERSHIP  Incumbent Independent Board Members own approximately 0.22% of Peregrine’s common stock  It has been over nine years since an Incumbent Independent Board Shares Director Member personally purchased shares in the open market Director Owned % Outstanding S

  23. Slide 23: Corp Gov Failing #2 – Excessive Compensation

    CORP GOV FAILING #2 – EXCESSIVE COMPENSATION Peregrine Director Total Compensation  Incumbent Independent Board Members were $800,000 each paid on average over $525,000 annually $700,000 over the last five years $600,000  In 2010, Incumbent Independent Board Members were each paid on average over

  24. Slide 24: Corp Gov Failing #2 – Excessive Compensation

    CORP GOV FAILING #2 – EXCESSIVE COMPENSATION Average Director Total Compensation Last Reported Fiscal Year $450,000 $413,800  Peregrine’s average Incumbent Independent $400,000 Board Member compensation in FY2017 was 48% higher than a group of multi-billion 48% higher $350,000 dollar companies incl

  25. Slide 25: Corp Gov Failing #2 – Excessive Compensation

    CORP GOV FAILING #2 – EXCESSIVE COMPENSATION  Incumbent Independent Board Peregrine’s FY2017 Peer Group Director Total Compensation Last Fiscal Year Member average director $450,000 $413,800 compensation in FY2017 was 165% $400,000 higher than the Company’s chosen $350,000 peer group average, and t

  26. Slide 26: Corp Gov Failing #3 – Lack of Experience

    CORP GOV FAILING #3 – LACK OF EXPERIENCE  Despite their outrageously high compensation, no Incumbent Independent Board Member possesses any prior experience Biologic Clinical with CDMOs or businesses Current Manufacturing Development related to it Director Profession Employer1 Experience? Experienc

  27. Slide 27: Corp Gov Failing #4 – Questionable Independence

    CORP GOV FAILING #4 – QUESTIONABLE INDEPENDENCE “…a director will not qualify as an ‘independent director’ if, in the opinion of our Board of Directors, that person has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.”

  28. Slide 28: Corp Gov Failing #5 – Consistent Failure on Boards

    CORP GOV FAILING #5 – CONSISTENT FAILURE ON BOARDS  Every company experienced triple-digit Fully Diluted Shares percentage increases in fully diluted shares Increase During Stock Performance outstanding during board tenures Director Company Board Tenure Tenure During Tenure  Companies often had no

  29. Slide 29: Shareholders Are Ready for Change

    SHAREHOLDERS ARE READY FOR CHANGE Peregrine % Voting Shares Withheld at Annual Meeting 40%  Institutional Shareholder Services (“ISS”) has recommended 35% “WITHHOLD” votes for all three Incumbent Independent Board Members in each of the last three years 30%  In FY2016, Incumbent Independent Board

  30. Slide 30: Conclusion

    CONCLUSION  Peregrine needs a fresh start at the Board level  An overhaul of Peregrine’s Board is justified given the Board’s history  We believe Peregrine’s Board has many deficiencies that must be addressed by independent directors with relevant industry experience who were not hand-picked by t

Peregrine Pharmaceuticals — Proxy Contest (October 2017) on 6ix